Uncategorized

Bristol Myers Squibb and 2seventy bio, Inc. announced results from the preplanned final progression-free survival analysis of KarMMa-3, the pivotal Phase 3, open-label, global, randomized controlled study evaluating Abecma compared with standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy.

During the ESMO Immuno-Oncology Congress 2023 held in Geneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest results of the Phase I clinical trial for QLS31905 in patients with advanced solid tumors through a poster presentation.

Johnson & Johnson announced an analysis from the Phase 1/2 MonumenTAL-1 study of TALVEY™ in patients with relapsed or refractory multiple myeloma showed that patients treated with TALVEY™ were subsequently treated effectively with several classes of therapy, including anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy as well as BCMA and anti-Fc receptor-like protein 5

El carcinoma hepatocelular (CHC) es una neoplasia maligna importante en todo el mundo

Prácticas esenciales para hospitales de cuidados intensivos en el uso de catéteres uretrales y opciones para la administración de urocultivos

The Indiana-based pharma shed shares after a study published Monday in JAMA showed “substantial” weight gain after patients discontinued treatment with the GLP-1 receptor agonist.

The collaboration will focus on Cosmo Intelligent Medical Devices’ GI Genius module, which Medtronic distributes globally.

Mitchell joined Hologic as vice president of sales and commercial excellence for the GYN surgical division in 2017.

Industry veteran Terika Richardson steps into the post, effective Monday.

Ransomware attacks are soaring in the healthcare sector, impacting more than 88 million people in the first 10 months of 2023, according to the HHS.